Drug Trial Radar · NCT07254429
COMPASS - COpenhagen MenoPAuSe Study
Last checked: Nov 20, 2026Latest source record: Mar 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
192
Planned (sponsor's estimate)
Start
Oct 2, 2025
Primary completion
Dec 2027
Study completion May 2028
Sponsor
- Lead sponsor
- Martin Blomberg JensenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 40 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
During menopause, estrogen levels drop while the level of another hormone - LH (luteinizing hormone) substantially increases. This hormonal shift is linked to bone Loss and other complications. Estrogen therapy can help, but some women avoid it due to the increased risk of blood clots and cancer. This project will investigate whether blocking LH could offer a safe alternative to alleviate symptoms and complications of menopause since it is known from previous research that high LH levels contribute to both bone deterioration and metabolic issues. The goal is to explore new treatment options that can improve health and quality of life for women both during and after menopause. This randomized clinical trial is a single center, sponsor-investigator-initiated single-blinded 8 weeks clinical trial with four parallel groups comparing the effect of an gonadotropin releasing hormone(GnRH)-analog with placebo, and with two additional arms given estrogen or testosterone on change on bone health in postmenopausal women with moderate-to-severe symptoms.
Conditions
- Menopausal Osteoporosis
- Bone Markers
Interventions
Triptorelin 11.25 mgDrug
Pamorelin 11.25 mg intramuscular injection once
Sodium Chloride 0.9%Drug
Saline intramuscular injection once
Estradiol (E2)Drug
Estreva gel 1.5 mg daily
TestosteroneDrug
Tostran gel 10 mg every other day
Placebo gelDrug
Placebo gel every day or every other day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in bone remodeling from baseline to week 8.Time frame: From baseline to week 8
- Change in bone remodeling from baseline to week 8.Time frame: From baseline to week 8
- Change in bone remodeling from baseline to week 8Time frame: From baseline to week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Division of Translational Endocrinology, Department of Endocrinology and Internal Medicine, Copenhagen University Hospital Herlev.
Herlev, Denmark · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.